Pacira BioSciences (PCRX) to Release Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX) will release its earnings data after the market closes on Tuesday, May 7th. Analysts expect Pacira BioSciences to post earnings of $0.64 per share for the quarter. Pacira BioSciences has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Pacira BioSciences (NASDAQ:PCRX) last posted its quarterly earnings data on Thursday, February 29th. The company reported $0.71 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.71. The firm had revenue of $181.24 million during the quarter, compared to analysts’ expectations of $180.60 million. Pacira BioSciences had a net margin of 6.22% and a return on equity of 12.81%. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pacira BioSciences Stock Up 2.4 %

Shares of NASDAQ PCRX opened at $27.86 on Monday. Pacira BioSciences has a 52-week low of $25.33 and a 52-week high of $43.81. The business’s 50 day moving average is $28.41 and its two-hundred day moving average is $29.54. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of 33.59 and a beta of 0.77. The company has a quick ratio of 4.17, a current ratio of 5.24 and a debt-to-equity ratio of 0.59.

Insider Buying and Selling

In other news, Director Gary W. Pace sold 1,066 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares of the company’s stock, valued at approximately $4,165,193.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Gary W. Pace sold 1,066 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the sale, the director now owns 140,384 shares in the company, valued at approximately $4,165,193.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gary W. Pace sold 90,000 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total transaction of $2,754,000.00. Following the completion of the transaction, the director now owns 22,127 shares of the company’s stock, valued at approximately $677,086.20. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Wedbush restated an “outperform” rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Thursday, February 8th. TheStreet raised shares of Pacira BioSciences from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 target price on shares of Pacira BioSciences in a research note on Tuesday, April 9th. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Pacira BioSciences in a report on Monday, March 4th. Finally, Royal Bank of Canada dropped their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. Eleven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pacira BioSciences has an average rating of “Buy” and an average target price of $49.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.